Despite major advances in cancer diagnostics and therapeutics, clinical outcomes for many patients remain suboptimal. A major challenge is the genetic and epigenetic heterogeneity of tumors, which drives highly variable responses to treatment across individuals. Addressing this complexity requires a more personalized approach.

Our group focuses on developing and leveraging Patient-Derived Organoid (PDO) models of different solid tumors to:

• • investigate cancer biology,
• • identify alternative actionable therapeutic targets, and
• • establish drug response profiling (DRP) platforms for personalized therapy.

We have already developed annotated living organoid biobanks for studying breast cancer and gallbladder diseases. Additionally, our state-of-the-art DROBAuT (Drug Response testing in Organoids using Bioprinting and Automation Technologies) facility enables us to perform high-throughput drug screening using tumor PDOs. Our long-term goal is to develop more personalized and effective, affordable treatment strategies for cancer patients.

We welcome collaborations and partnerships with academic and industry groups interested in translational cancer research.

“Alone we can do so little; together we can do so much.” — Helen Keller